HealthcareGlobal Onychomycosis (Tinea Unguium) Drug Market by Manufacturers, Countries, Type and Application, Forecast to 2022

  • RnM1150396
  • |
  • 3 April, 2017
  • |
  • Global
  • |
  • 115 pages
  • |
  • GlobalInfoResearch
  • |
  • Healthcare

"Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.
Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease."

Scope of the Report:
This report focuses on the Onychomycosis (Tinea Unguium) Drug in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
Johnson & Johnson
GSK
Novartis
Pfizer
Valeant Pharma
Kaken Pharmaceutical
Galderma
Xiuzheng Pharmaceutical
Letai
Qilu Pharmaceutical

Market Segment by Regions, regional analysis covers
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Columbia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Oral
External

Market Segment by Applications, can be divided into
Age under 18
Age 18-50
Age above 50

There are 15 Chapters to deeply display the global Onychomycosis (Tinea Unguium) Drug market.

Chapter 1, to describe Onychomycosis (Tinea Unguium) Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Onychomycosis (Tinea Unguium) Drug, with sales, revenue, and price of Onychomycosis (Tinea Unguium) Drug, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Onychomycosis (Tinea Unguium) Drug, for each region, from 2012 to 2017;

Chapter 5, 6, 7, 8 and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;

Chapter 12, Onychomycosis (Tinea Unguium) Drug market forecast, by regions, type and application, with sales and revenue, from 2017 to 2022;

Chapter 13, 14 and 15, to describe Onychomycosis (Tinea Unguium) Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Table of Contents

1 Market Overview
1.1 Onychomycosis (Tinea Unguium) Drug Introduction
1.2 Market Analysis by Type
1.2.1 Oral
1.2.2 External
1.3 Market Analysis by Applications
1.3.1 Age under 18
1.3.2 Age 18-50
1.3.3 Age above 50
1.4 Market Analysis by Regions
1.4.1 North America (USA, Canada and Mexico)
1.4.1.1 USA Market States and Outlook (2012-2022)
1.4.1.2 Canada Market States and Outlook (2012-2022)
1.4.1.3 Mexico Market States and Outlook (2012-2022)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2012-2022)
1.4.2.2 France Market States and Outlook (2012-2022)
1.4.2.3 UK Market States and Outlook (2012-2022)
1.4.2.4 Russia Market States and Outlook (2012-2022)
1.4.2.5 Italy Market States and Outlook (2012-2022)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2012-2022)
1.4.3.2 Japan Market States and Outlook (2012-2022)
1.4.3.3 Korea Market States and Outlook (2012-2022)
1.4.3.4 India Market States and Outlook (2012-2022)
1.4.3.5 Southeast Asia Market States and Outlook (2012-2022)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2012-2022)
1.4.4.2 Egypt Market States and Outlook (2012-2022)
1.4.4.3 Saudi Arabia Market States and Outlook (2012-2022)
1.4.4.4 South Africa Market States and Outlook (2012-2022)
1.4.4.5 Nigeria Market States and Outlook (2012-2022)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Johnson & Johnson
2.1.1 Business Overview
2.1.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Johnson & Johnson Onychomycosis (Tinea Unguium) Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 GSK
2.2.1 Business Overview
2.2.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 GSK Onychomycosis (Tinea Unguium) Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Novartis Onychomycosis (Tinea Unguium) Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Pfizer Onychomycosis (Tinea Unguium) Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Valeant Pharma
2.5.1 Business Overview
2.5.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Kaken Pharmaceutical
2.6.1 Business Overview
2.6.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Kaken Pharmaceutical Onychomycosis (Tinea Unguium) Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Galderma
2.7.1 Business Overview
2.7.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 Galderma Onychomycosis (Tinea Unguium) Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Xiuzheng Pharmaceutical
2.8.1 Business Overview
2.8.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Letai
2.9.1 Business Overview
2.9.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.9.2.1 Type 1
2.9.2.2 Type 2
2.9.3 Letai Onychomycosis (Tinea Unguium) Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Qilu Pharmaceutical
2.10.1 Business Overview
2.10.2 Onychomycosis (Tinea Unguium) Drug Type and Applications
2.10.2.1 Type 1
2.10.2.2 Type 2
2.10.3 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Onychomycosis (Tinea Unguium) Drug Market Competition, by Manufacturer
3.1 Global Onychomycosis (Tinea Unguium) Drug Sales and Market Share by Manufacturer
3.2 Global Onychomycosis (Tinea Unguium) Drug Revenue and Market Share by Manufacturer
3.3 Market Concentration Rate
3.3.1 Top 3 Onychomycosis (Tinea Unguium) Drug Manufacturer Market Share
3.3.2 Top 6 Onychomycosis (Tinea Unguium) Drug Manufacturer Market Share
3.4 Market Competition Trend
4 Global Onychomycosis (Tinea Unguium) Drug Market Analysis by Regions
4.1 Global Onychomycosis (Tinea Unguium) Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Onychomycosis (Tinea Unguium) Drug Sales by Regions (2012-2017)
4.1.2 Global Onychomycosis (Tinea Unguium) Drug Revenue by Regions (2012-2017)
4.2 North America Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
4.3 Europe Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
4.4 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
4.5 South America Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
4.6 Middle East and Africa Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
5 North America Onychomycosis (Tinea Unguium) Drug by Countries
5.1 North America Onychomycosis (Tinea Unguium) Drug Sales, Revenue and Market Share by Countries
5.1.1 North America Onychomycosis (Tinea Unguium) Drug Sales by Countries (2012-2017)
5.1.2 North America Onychomycosis (Tinea Unguium) Drug Revenue by Countries (2012-2017)
5.2 USA Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
5.3 Canada Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
5.4 Mexico Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
6 Europe Onychomycosis (Tinea Unguium) Drug by Countries
6.1 Europe Onychomycosis (Tinea Unguium) Drug Sales, Revenue and Market Share by Countries
6.1.1 Europe Onychomycosis (Tinea Unguium) Drug Sales by Countries (2012-2017)
6.1.2 Europe Onychomycosis (Tinea Unguium) Drug Revenue by Countries (2012-2017)
6.2 Germany Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
6.3 UK Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
6.4 France Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
6.5 Russia Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
6.6 Italy Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
7 Asia-Pacific Onychomycosis (Tinea Unguium) Drug by Countries
7.1 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Sales by Countries (2012-2017)
7.1.2 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Revenue by Countries (2012-2017)
7.2 China Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
7.3 Japan Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
7.4 Korea Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
7.5 India Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
7.6 Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
8 South America Onychomycosis (Tinea Unguium) Drug by Countries
8.1 South America Onychomycosis (Tinea Unguium) Drug Sales, Revenue and Market Share by Countries
8.1.1 South America Onychomycosis (Tinea Unguium) Drug Sales by Countries (2012-2017)
8.1.2 South America Onychomycosis (Tinea Unguium) Drug Revenue by Countries (2012-2017)
8.2 Brazil Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
8.3 Argentina Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
8.4 Columbia Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
9 Middle East and Africa Onychomycosis (Tinea Unguium) Drug by Countries
9.1 Middle East and Africa Onychomycosis (Tinea Unguium) Drug Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Onychomycosis (Tinea Unguium) Drug Sales by Countries (2012-2017)
9.1.2 Middle East and Africa Onychomycosis (Tinea Unguium) Drug Revenue by Countries (2012-2017)
9.2 Saudi Arabia Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
9.3 UAE Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
9.4 Egypt Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
9.5 Nigeria Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
9.6 South Africa Onychomycosis (Tinea Unguium) Drug Sales and Growth (2012-2017)
10 Global Onychomycosis (Tinea Unguium) Drug Market Segment by Type
10.1 Global Onychomycosis (Tinea Unguium) Drug Sales, Revenue and Market Share by Type (2012-2017)
10.1.1 Global Onychomycosis (Tinea Unguium) Drug Sales and Market Share by Type (2012-2017)
10.1.2 Global Onychomycosis (Tinea Unguium) Drug Revenue and Market Share by Type (2012-2017)
10.2 Oral Sales Growth and Price
10.2.1 Global Oral Sales Growth (2012-2017)
10.2.2 Global Oral Price (2012-2017)
10.3 External Sales Growth and Price
10.3.1 Global External Sales Growth (2012-2017)
10.3.2 Global External Price (2012-2017)
11 Global Onychomycosis (Tinea Unguium) Drug Market Segment by Application
11.1 Global Onychomycosis (Tinea Unguium) Drug Sales Market Share by Application (2012-2017)
11.2 Age under 18 Sales Growth (2012-2017)
11.3 Age 18-50 Sales Growth (2012-2017)
11.4 Age above 50 Sales Growth (2012-2017)
12 Onychomycosis (Tinea Unguium) Drug Market Forecast (2017-2022)
12.1 Global Onychomycosis (Tinea Unguium) Drug Sales, Revenue and Growth Rate (2017-2022)
12.2 Onychomycosis (Tinea Unguium) Drug Market Forecast by Regions (2017-2022)
12.2.1 North America Onychomycosis (Tinea Unguium) Drug Market Forecast (2017-2022)
12.2.2 Europe Onychomycosis (Tinea Unguium) Drug Market Forecast (2017-2022)
12.2.3 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Forecast (2017-2022)
12.2.4 South America Onychomycosis (Tinea Unguium) Drug Market Forecast (2017-2022)
12.2.5 Middle East and Africa Onychomycosis (Tinea Unguium) Drug Market Forecast (2017-2022)
12.3 Onychomycosis (Tinea Unguium) Drug Market Forecast by Type (2017-2022)
12.4 Onychomycosis (Tinea Unguium) Drug Market Forecast by Application (2017-2022)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Analyst Introduction
15.3 Data Source

captcha
Please enter code
captcha
Please enter code

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

captcha
Please enter code

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,480.00
$4,680.00
2,336.82
3,142.62
3,202.30
4,306.54
421,567.20
566,935.20
230,770.63
310,346.71
Add To Cart Credit card Logo

Related Reports


Reason to Buy